Claims for Patent: 4,889,803

Summary for Patent: 4,889,803

Title:	Production of interferon gamma
Abstract:	Interferon .gamma. is produced in highly purified form (activity exceeding 10.sup.8 units/ml-day) by CHO cells cotransformed by a first plasmid bearing the genomic human interferon gene under the control of the SV40 early promoter, and a second plasmid bearing a DHFR gene under similar control. Methotrexate selection yielded a clone which was a particularly efficient producer. Production of interferon .gamma. may also be facilitated by a Harvey sarcoma virus enhancer sequence.
Inventor(s):	Revel; Michel (Rehovot, IL), Rubinstein; Menachem (Givat-Shmuel, IL), Mory; Yvez (Rehovot, IL)
Assignee:	Yeda Research & Development Co., Ltd. (Rehovot, IL)
Application Number:	06/727,673
Patent Claims:	1. A method of producing human gamma interferon which comprises (a) providing Chinese hamster ovary cells bearing a first DNA sequence which codes on expression for human gamma interferon and includes at least one intron of the genomic human gamma interferon gene, said first DNA sequence being operably linked to a constitutive promoter functional in such cells, said promoter being a non-interferon promoter, said cells also bearing a gene coding on expression for dihydrofolate reductase, said gene likewise being operably linked to a constitutive promoter functional in such cells; (b) cultivating the cells in a medium containing methotrexate at a level toxic to cells which do not constitutively express dihydrofolate reductase, whereby the DHFR gene and the gamma interferon gene are co-amplified, and (c) cultivating such cells under conditions in which the cells constitutively express human gamma interferon in recoverable quantities. 2. The method of claim 1 wherein the first DNA sequence comprises the entire sequence of the genomic human gamma interferon gene. 3. The method of claim 2 wherein such cells produce human gamma interferon at a rate of at least about 190,000 units/ml-day. 4. The method of claim 2 wherein such cells produce human gamma interferon at a rate of at least about 260,000 units/ml-day. 5. The method of claim 2 wherein such cells produce human gamma interferon at a rate of at least about 800,000 units/ml-day. 6. The method of claim 2 wherein the cells are resistant to at least about 20 nM methotrexate and the DHFR and gamma interferon genes are co-amplified with at least about 20 nM methoxtrexate. 7. The method of claim 2 wherein the cells are resistant to at least about 50 nM methotrexate and the DHFR and gamma interferon genes are co-amplified with at least about 50 nM methotrexate. 8. The method of claim 2 wherein the cells are resistant to at least about 300 mM methotrexate and the DHFR and gamma interferon genes are co-amplified with at least about 300 nM methotrexate. 9. The method of claim 2 wherein after amplification with methotrexate, such cells contain at least about 50 times more human gamma interferon-specific mRNA than such cells contained prior to amplification. 10. The method of claim 2 wherein the constitutive promoter operably linked to the first DNA sequence is the SV40 early promoter or a derivative thereof which includes the 72 base pair repeat of the SV40 early promoter. 11. The method of claim 10, wherein the Harvey murine sarcoma virus enhancer sequence is operably associated with said first DNA sequence and enhances expression of the human gamma interferon encoded by that sequence. 12. Recombinant DNA molecules having the identifying characteristics of the vector pSVEgamma121. 13. Chinese hamster ovary cells cotransformed with pSVEgamma121 and a plasmid conferring a DHFR.sup.+ phenotype. 14. The method of claim 1 wherein the cells bear the plasmid pSVEgamma121. 15. The method of claim 2 wherein cells bearing the plasmid pSVEgamma121 are cultivated in step (b) in a medium containing at least 300 nM methotrexate, and the cells produce interferon gamma at a rate of at least about 400,000 units/ml-day.

Details for Patent 4,889,803

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2006-12-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2006-12-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2006-12-26